Radiopharm Theranostics Limited (AU:RAD)
ASX:RAD
161Tb Rad402
Castration-Resistant Prostate Cancer
Phase I/II
Not Yet Recruiting
A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
Nov 15, 2025
―
177Lu-Betabart
Cervical Cancer, Ovarian Cancer, Colorectal Cancer, Castration-Resistant Prostate Cancer (Crpc), Endometrial Cancer, Esophageal Squamous Cell Carcinoma (Escc), Nsclc (Non-Small Cell Lung Cancer), Tnbc, Triple Negative Breast Cancer, Small Cell Lung Cancer (Sclc ), Head &Amp; Neck Squamous Cell Carcinoma (Hnscc)
Phase I/II
Recruiting
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Sep 11, 2025
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Radiopharm Theranostics Limited (RAD) have in its pipeline
RAD is currently developing the following drugs: Lnth-2403, 161Tb Rad402, 177Lu-Betabart. These drug candidates are in various stages of clinical development as the company works toward FDA approval.